NAMUR, Belgium, May 26,
2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX)
today announced it is scheduled to present at multiple investor
conferences in June.
Dr. Scott Powell, Executive Vice
President of Volition, will provide an update on Volition's
business, clinical, regulatory and operational milestones, as well
as the Company's product launch of its Nu.QTM Colorectal
Cancer Screening Triage Test.
Details of the conferences are as follows
Conference:
|
6th Annual
SeeThruEquity Microcap Investor Conference
|
Date:
|
Thursday, June 1,
2017
|
Location:
|
Convene Conference
Center, New York, NY
|
|
|
Conference:
|
LD Micro
Invitational
|
Date:
|
Wednesday, June 7,
2017
|
Time:
|
10:30 a.m.
PDT
|
Location:
|
Luxe Sunset Bel Air
Hotel, Los Angeles, CA
|
|
|
Conference:
|
2017 Marcum MicroCap
Conference
|
Date:
|
Friday, June 16,
2017
|
Time:
|
10:00 a.m.
EDT
|
Location:
|
Grand Hyatt Hotel,
New York, NY
|
Persons attending any of the above-referenced conferences who
would like to schedule a 1-on-1 meeting with Volition management
during such conference may do so by contacting Tirth Patel of Edison Advisors at
tpatel@edisongroup.com or Scott
Powell, Executive Vice President of Volition, at
S.Powell@volitionrx.com.
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid --
an indication that disease is present.
As cancer screening programs become more and more widespread,
our products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
New York, Texas, and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and
their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-multiple-investor-conferences-in-june-300464334.html
SOURCE VolitionRx Limited